Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalaprilat Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalaprilat Anhydrous SCHEMBL37288 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL4954583 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8149345 | 1.00 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8903287 | 0.99 | ACE (0.96) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8836365 | 0.99 | ACE (0.96) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL3090322 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL6106603 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL12737170 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL2406720 | 0.99 | ACE (1.00) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230398130-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-12-14 | — | — | US | disclosed |
| US-20230053688-A1 | METHODS TO ALTER LATENCY IN EBV+ MALIGNANCIES | CORNELL UNIVERSITY | 2023-02-23 | — | — | US | disclosed |
| US-20220323406-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-13 | — | — | US | disclosed |
| US-11179412-B2 | Methods of treating conditions involving elevated inflammatory response | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190167710-A1 | Methods of Treating Conditions Involving Elevated Inflammatory Response | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-06 | — | — | US | disclosed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-104530417-B | A kind of multiple functionalized H types polyethyleneglycol derivative and preparation method thereof | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-104530415-B | A kind of different functionalization Y types polyethyleneglycol derivative, preparation method and its bio-related substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-104530413-B | A kind of bio-related substance of multiple functionalized H types polyethyleneglycol derivative modification | 厦门赛诺邦格生物科技股份有限公司 | 2017-08-25 | — | — | CN | disclosed |
| CN-104725628-A | Single functional branched polyethylene glycol containing degradable radical, preparation method and biorelevant substance of single functional branched polyethylene glycol | XIAMEN SINOPEG BIOTECH CO LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-104530415-A | Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104530417-A | Multifunctional H-type polyethylene glycol derivative and preparation method thereof | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
| CN-104530413-A | Biologically related substances modified by multifunctional H-type polyethylene glycol derivative | XIAMEN SINOPEG BIOTECH INC | 2015-04-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | ACE 380/4885LMNA 3941/4885SMN1; SMN2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.